Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood

A homocysteine, chronic disease technology, applied in the pharmaceutical field, to achieve huge market application prospects, the effect of preventing and treating cardiovascular damage

Pending Publication Date: 2020-03-20
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Tanshinone IIA sodium sulfonate injection has been widely used in clinical treatment of coronary heart disease, angina pectoris, ventricular premature beats and other diseases. Anti-cardiovascular damage caused by homocysteine ​​has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood
  • Application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood
  • Application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1 (Protective Effect of Sodium Tanshinone IIA Sulfonate on Endothelial Cell Damage Caused by Homocysteine ​​in Vitro)

[0023] The main reagents in the experiment: Homocysteine ​​was purchased from Sigma Company, its article number and specification: H4628-5G; MTT was purchased from Sigma Company, its article number and specification was: M2128-5G; Tanshinone IIA sodium sulfonate was purchased from Chengdu Mansite Company, its article number and specification are: A0058-20mg. HUVEC endothelial cells were purchased from ATCC Company in the United States, and its article number is: CRL-1730;

[0024] 1.1 Toxic effect of homocysteine ​​on vascular endothelial cells

[0025] Human umbilical vein endothelial cells were divided into 1X10 4 Seed / mL density into 96-well plate, 100 μl per well, in CO 2 Incubator (37°C, 5% CO 2 ) for 24 hours. According to the blank control group and different dosage groups of homocysteine ​​(1, 2, 4, 8 mM), the drugs were added for ...

Embodiment 2

[0030] Example 2 (Protective Effect of Sodium Tanshinone IIA Sulfonate on Cardiomyocyte Injury Caused by Homocysteine ​​in Vitro)

[0031] The main reagents in the experiment: Homocysteine ​​was purchased from Sigma Company, its article number and specification: H4628-5G; MTT was purchased from Sigma Company, its article number and specification was: M2128-5G; Tanshinone IIA sodium sulfonate was purchased from Chengdu Mansite Company, its article number and specification are: A0058-20mg. H9c2 cardiomyocytes were purchased from the Cell Bank of Shanghai Chinese Academy of Sciences, and its item number is: GNR 5;

[0032] 2.1 Toxic effect of homocysteine ​​on cardiomyocytes

[0033] Human cardiomyocytes were divided into 0.8X10 4 Seed / mL density into 96-well plate, 100 μl per well, in CO 2 Incubator (37°C, 5% CO 2 ) for 24 hours. According to the blank control group and different dosage groups of homocysteine ​​(0.5, 1, 2, 4mM), drug was added for 24 hours respectively, and...

Embodiment 3

[0036] Example 3 (Protective Effect of Sodium Tanshinone IIA Sulfonate on Rat Thoracic Aorta Diastolic and Contractile Function Damage Caused by Homocysteine ​​in Vitro)

[0037] The main reagents in the experiment: homocysteine ​​was purchased from sigma company, its article number and specification: H4628-5G; Tanshinone IIA sodium sulfonate was purchased from Chengdu Mansite Company, its article number and specification were: A0058-20mg. Wistar rats were provided by the SPF Animal Experiment Center of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.

[0038] 3.1 Injury effect of homocysteine ​​on diastolic function of rat thoracic aorta

[0039] After the rat thoracic aortic ring was isolated, it was cultured in the Taimeng tissue perfusion system and the changes of its systolic and diastolic tension were recorded. The culture conditions are: Krebs physiological equilibrium liquid, 37°C, 5% carbon dioxide, 95% oxygen. After the blood vess...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of sodium tanshinone IIA sulfonate in preparation of medicines for treating acute or chronic diseases accompanied with increase of homocysteine in blood, alone oras an effective component. Vascular endothelial cells, myocardial cells, nerve cells and isolated blood vessel models are used to simulate the damage effect of the homocysteine on cardiovascular and cerebrovascular systems, it discovers that sodium tanshinone IIA sulfonate has a protection and / or treatment effect on the cardiovascular and cerebrovascular damages caused by the homocysteine, and theblank of protection and / or treatment medicines for resisting the cardiovascular and cerebrovascular damages caused by the homocysteine is filled up. The medicines provided by the invention are suitable for diseases causing abnormal increase of the homocysteine in the blood, can play a role in protecting and / or treating cardiovascular and cerebrovascular injuries caused by resisting the homocysteine only by reaching effective concentration in the blood, and provide a better choice for treating the cardiovascular and cerebrovascular injuries of diseases causing the increase of the homocysteinein the blood.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the application of sodium tanshinone IIA sulfonate in the preparation of prevention and / or treatment of diseases related to cardiovascular and cerebrovascular injury caused by high homocysteine Background technique [0002] Homocysteine ​​is an independent risk factor for coronary heart disease, atherosclerosis and other cardiovascular and cerebrovascular diseases. Its pathogenic mechanism includes affecting vascular endothelial function, promoting smooth muscle proliferation, promoting thrombosis, and cardiovascular toxicity. The clinical manifestations of some kidney diseases, liver diseases, metabolic diseases, nervous system diseases, cancer, and certain drug intakes are abnormally elevated homocysteine ​​in the blood. At present, the clinical drugs for the prevention and treatment of hyperhomocysteine ​​are mainly compound preparations containing B vitamins and folic acid that intervene...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P9/10A61P9/12A61P9/04A61P9/06A61P25/28A61P25/06A61P19/10A61P13/12A61P25/18A61P27/12A61P27/06A61P35/00A61P3/10
CPCA61K31/58A61P9/10A61P9/12A61P9/04A61P9/06A61P25/28A61P25/06A61P19/10A61P13/12A61P25/18A61P27/12A61P27/06A61P35/00A61P3/10
Inventor 唐靖一陈昕琳周忠焱马子霖赵外荣肖颖施雯婷
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com